Oruka amends IL-23 license agreement with Paragon expanding field to all therapeutic areas
Oruka Therapeutics and Paragon Therapeutics executed a first amendment to their IL-23 license agreement dated May 29, 2026, expanding the Field definition from inflammatory bowel disease to all therapeutic areas. The amendment broadens Oruka's development rights and commercial op
View filing at SEC.gov →